A stem cell IV therapy is an infusion in which cultured stem cells are delivered into a vein through a drip. Human research on intravenous stem cells is still early. The most rigorous trial we found tested safety in a small group of frail older adults, not healthy people seeking anti-aging, and it did not show that infusions slow or reverse aging. The US Food and Drug Administration (FDA) lists its licensed cellular and gene therapy products, updated 30 October 2026, which include HPC cord blood products and RYONCIL, a mesenchymal stromal cell product. Anti-aging is not among the approved uses of the cord blood products.

What an infusion involves

Most clinics describe the same basic sequence, although details vary by product and by country:

  • Source of the cells. The cells come either from the patient's own tissue, usually fat or bone marrow, or from a donor, most often umbilical cord tissue. Donor cells are called allogeneic. Donor cells carry a different risk profile from the patient's own cells because the patient's immune system may react to them.
  • Culture. The cells are grown in a laboratory before use. Culturing takes time, so an autologous treatment can require a separate collection visit and a later treatment visit.
  • Infusion. A nurse or physician places a catheter in a vein and runs the cells in over a set period. Patients are usually watched during the drip and afterward for reactions such as fever, chills or an allergic response.
  • Follow-up. The treating team should explain what to watch for after the patient goes home and who to contact if symptoms appear.

Every step carries its own risks, and a clinic should be able to name the cell source, the culture method and the infusion route for the specific treatment being offered. Our overview of stem cell therapy in Japan explains how these steps fit into the wider process.

What the research shows

The most rigorous study we found on intravenous stem cells in aging was a phase II, randomized, double-blind, placebo-controlled trial published in 2017 in the Journals of Gerontology. Its authors reported the following design details:

Close-up of a clear IV fluid bag hanging from a metal pole with tubing and a clamp, with a blurred person in blue scrubs in the background.

  • The trial enrolled 30 people with frailty, with a mean age of about 75.
  • Participants received intravenous allogeneic mesenchymal stem cells at 100 million or 200 million cells, or a placebo.
  • The primary endpoint was safety, measured as treatment-emergent serious adverse events.

Two points matter for readers. First, the population was frail older adults, so the study does not show that stem cells help healthy people look or feel younger. Second, the study was small and tested dose levels, not long-term benefit. A safety endpoint can show that a treatment was tolerated in a trial; it cannot show that the treatment works. The study's source is listed at the end of this article.

The FDA has taken a clear position on unapproved stem cell products. It says such products have not been adequately studied under an investigational new drug (IND) application to demonstrate safety and effectiveness. The FDA also reports receiving reports of blindness, tumor formation and infections linked to unapproved products. Those warnings apply to stem cell products sold outside approved uses.

Why anti-aging claims lack proof

Claims that stem cell infusions slow aging rest on a chain of inferences. Mesenchymal stem cells are thought to act partly by releasing signaling molecules that influence inflammation and tissue repair. Aging involves chronic inflammation and reduced repair capacity. From there, some clinics argue that infusions should reverse aging. Each link is plausible, but none has been tested in a controlled trial that measures a meaningful outcome such as healthy lifespan or functional ability in ordinary adults.

The frailty trial measured walking endurance and some immune markers. It did not measure skin appearance, energy or biological age, which are the outcomes most often advertised. Advertised results from individual patients are not controlled evidence.

How Japan regulates IV stem cell treatments

In Japan, clinics that offer regenerative medicine must file a treatment plan for each technique under the Act on the Safety of Regenerative Medicine. The Act sorts treatments into three risk classes, and the class determines the review and waiting rules:

A hand holding a clear IV fluid bag connected to tubing and an infusion pump in a clinical room.

  • Cultured stem cells from the patient's own fat fall into Class II under the Enforcement Regulations, which means a specially certified committee reviews the plan and no waiting period applies under the Act.
  • Stem cells from a donor, such as umbilical cord cells, fall into Class I. A Class I plan is filed with the Minister of Health, Labour and Welfare, and the clinic may not provide the treatment until 90 days after filing, unless the period is shortened or extended.

The Act excludes clinical trials and approved products used as approved. An IV infusion offered as self-pay treatment outside a trial therefore sits inside the Act's framework, but a filed plan only shows that the clinic completed the legal procedure. It does not show that the treatment works for a given condition.

Most regenerative medicine in Japan is self-pay free treatment (jiyū shinryō), outside public health insurance, and the clinic sets its own price. The price is therefore a matter for a written quote, not something a public list can confirm.

Questions to ask before deciding

  • Are the cells from me or from a donor, and in which class is the treatment filed?
  • Which certified committee reviewed the plan, and when was it filed?
  • What published human evidence exists for the specific condition I have, and what outcome does it measure?
  • What are the infusion-day risks, and what happens if I react during or after the drip?
  • Who manages follow-up in my home country, and how are adverse events reported?

Close-up of an arm with a clear IV tube taped to the forearm resting on patterned fabric beside a gray knit blanket.

If the answers are vague, send the clinic's name and the treatment description to our advisors, and we will check whether the clinic has filed a provision plan for that treatment. You can also review how the system is organized on our how Japan regulates regenerative medicine page, and start with our pre-screening form if you want help deciding whether the treatment fits your situation.

Frequently asked questions

Does a stem cell IV infusion reverse aging?

No clinical evidence shows that. The most rigorous human study we found tested intravenous stem cells in frail older adults and measured safety and a few body markers. It did not measure biological age, and it did not test healthy people seeking anti-aging.

Is stem cell IV therapy approved by the FDA?

The FDA's list of licensed cellular and gene therapy products, updated 30 October 2026, includes HPC cord blood products and RYONCIL, a mesenchymal stromal cell product. Anti-aging is not among the approved uses of the cord blood products.

Is stem cell IV therapy legal in Japan?

It is legal when the clinic has filed a provision plan for that technique under the Safety Act and the treatment is offered as self-pay care. Filing does not confirm that the treatment is effective, and a clinic that has not filed a plan may not lawfully provide it.

What are the main risks of an IV stem cell infusion?

The risks include reactions during or after the drip, infection and contamination during cell preparation, and immune reactions when donor cells are used. Long-term safety data are limited. Our stem cell therapy side effects article covers each risk in more detail.

Why do prices for IV stem cell therapy vary so much?

Prices are set by each clinic because the treatment is self-pay. Cell source, culture method, number of cells, number of infusions and the need for more than one trip all change the total. Ask for a line-by-line breakdown.

Sources: Tompkins et al., "Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial," Journals of Gerontology Series A 2017, doi:10.1093/gerona/glx137 (abstract); FDA, "Important Patient and Consumer Information About Regenerative Medicine Therapies"; FDA, "Approved Cellular and Gene Therapy Products"; FDA, "HPC, Cord Blood"; Japan Act on the Safety of Regenerative Medicine (Act No. 85 of 2013) and Enforcement Regulations, e-Gov text. Checked November 2026; MHLW (or the relevant body) publications prevail.

Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.